Women's Health

New Test Outperforms CA-125 in Ovarian Cancer Detection

New Test Outperforms CA-125 in Ovarian Cancer Detection

New Test Outperforms CA-125 in Ovarian Cancer Detection

Recent studies conducted in the United States and in Europe have effectively demonstrated the potential of a Parasortix-based blood test in outperforming current tests used to diagnose ovarian cancer. ANGLE, a world-leading liquid biopsy company, has currently invented a cell separation technology system, known as Parasortix, which can be used to capture cancer cells circulating in the blood by performing simple blood tests. The Parasortix-based blood test involves taking a blood sample from a patient and capturing circulating tumor cells (CTCs) from the sample in a small microscope slide-like element. A reverse flow system then analyzes the viable cells and once recognized, the RNA information within the cells are used to notify doctors about the patient’s condition and the most appropriate treatment method based on their individual case. More specifically, the blood test is used to make a distinction between benign and malignant tumors.